The kinetics of hepatitis C virus

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 4, 2006, Pages 339-342

  Herrmann, Eva ^a,b,c   Zeuzem, Stefan ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Efficiency of antiviral therapy; Interferon; Prediction of viral response; Ribavirin; Viral dynamics

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PURINE NUCLEOSIDE DERIVATIVE; RIBAVIRIN; VIRUS RNA;

CELL LOSS; CONFERENCE PAPER; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KINETICS; MATHEMATICAL MODEL; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; MODELS, BIOLOGICAL; RIBAVIRIN; RNA, VIRAL;

EID: 33645108434     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200604000-00006     Document Type: Conference Paper

References (54)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35-S46.
3. El Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36:S74-S83.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
7. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22:1050-1056.
8. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
9. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
10. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31:211-218.
11. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-1672.
12. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395-403.
13. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 kD). J Hepatol 2002; 37:500-506.
14. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36:S185-S194.
15. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37:600-609.
16. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37:1343-1350.
17. Layden-Almer JE, Layden TJ. Viral kinetics in hepatitis C virus: special patient populations. Semin Liver Dis 2003; 23 (suppl 1):29-33.
18. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140:370-381.
19. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-999.
20. ••Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107. This article introduced the basic model of HCV viral kinetics which forms the starting point of all recent hepatitis C viral kinetic analysis.
21. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120:1438-1447.
22. Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepatol 2002; 9:340-345.
23. • Colombatto P, Civitano L, Oliveri F, Coco B, Ciccorossi P, Flichman D, et al. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther 2003; 8:519-530. This article introduced a new model of hepatitis C viral kinetic analysis by using ALT levels for long-term modelling of the infected cell compartment and viral response.
24. Cotler SJ, Layden JE, Neumann AU, Jensen DM. First phase hepatitis C viral kinetics in previous nonresponder patients. J Viral Hepatol 2003; 10:43-49.
25. Karino Y, Toyota J, Sugawara M, Miyazaki K, Kuwata Y, Yamazaki K, et al. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2003; 18:404-410.
26. Brouwer JT, Nevens F, Kleter B, Elewaut A, Adler M, Brenard R, et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol 1998; 28:951-959.
27. Castro FJ, Esteban JI, Juarez A, Sauleda S, Viladomiu L, Martell M, et al. Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. J Viral Hepatol 2002; 9:202-207.
28. Liu LW, Tomlinson G, Mazzulli T, Murray A, Heathcote J. Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Can J Gastroenterol 2003; 17:483-487.
29. Nguyen TT, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, Lindsay KL, et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepatol 1996; 3:75-78.
30. • Zeuzem S, Schmidt JM, Lee JH, Rüster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23:366-371. This article introduced the first compartment model for hepatitis C viral kinetics which was already able to fit a biphasic viral decline.
31. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226-231.
32. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28:245-252.
33. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182:28-35.
34. • Bekkering FC, Neumann AU, Brouwer JT, Levi-Drummer RS, Schalm SW. Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol 2001; 1:14. In this article, a model was introduced that uses a modification of the efficiency factor during antiviral treatment to model dose reduction.
35. Halfon P, Neumann AU, Bourliere M, Rieu A, Chadapaud S, Khiri H, et al. Slow viral dynamics of hepatitis C virus genotype 4. J Viral Hepatol 2003; 10:351-353.
36. • Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358. This article introduced a triphasic model and uses a non-constant compartment of target cells for data fit.
37. • Powers KA, Dixit NM, Ribeiro RM, Golia P, Talal AH, Perelson AS. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 2003; 23 (suppl 1):13-18. This article introduced a complex compartment model where the efficiency in blocking virus production is modelled on the base of individual pharmacokinetics.
38. • Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003; 38:509-517. This article introduced a modification of the basic viral kinetic model by an additional ALT compartment.
39. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126:703-714.
40. Talal AH, Shata MT, Markatou M, Dorante G, Chadburn A, Koch R, et al. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immune Defic Syndr 2004; 35:103-113.
41. Kronenberger B, Herrmann E, Micol F, von Wagner M, Zeuzem S. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 2004; 40:1442-1449.
42. • Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432:922-924. This recent article introduces a hepatitis C viral kinetic model with different viral compartments to model a mutagenetic effect of ribavirin. This model can explain controversial results on ribavirin effects on the initial viral kinetics.
43. Sherman KE, Norah JS, Rouster SD, Peters M, Koziel MJ, Chung RT, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus infected patients. Gastroenterology 2005; 128:313-327.
44. Chung RT, He W, Saquib A, Contreras AM, Xavier RJ, Chawla A, et al. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc Natl Acad Sci USA 2001; 98:9847-9852.
45. Zhu H, Zhao H, Collins CD, Eckenrode SE, Run Q, Mclndoe RA, et al. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 2003; 37:1180-1188.
46. Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35:930-936.
47. Bergmann C, Layden JE, Levy-Drummer RS, Layden TJ, Haagmans BL, Neumann AU. Clinical implications of a new triphasic model of hepatitis C viral kinetics during IFN-alpha therapy. Hepatology 2001; 33 (suppl):345A.
48. Sentjens RE, Weegink CJ, Beld MG, Cooreman MC, Reesink HW. Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily. Eur J Gastroenterol Hepatol 2002; 14:833-840.
49. Lake-Bakaar G, Ruffini L, Kuzmic P. Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon. Dig Dis Sci 2003; 48:126-139.
50. Neumann AU, Dahari H, Conrad A, Plotz G, McHutchison JG. Early prediction and mechanism of the ribavirin/IFN-α dual therapy effect on chronic hepatitis C virus (HCV). Hepatology 1999; 30:309A.
51. Berg T, Kaul T, Naumann U, Wiedenmann B, Hopf U. Einfluss von Ribavirin auf die Dynamik der Hepatitis-C-Virämie bei Interferon-α-behandelten Patienten mit Response oder Nonresponse. Z Gastroenterol 2000; 38:881-886.
52. Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003; 188:1498-1507.
53. Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, et al. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepatol 2003; 10:37-42.
54. Layden TJ, Layden JE, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J Viral Hepatol 2002; 9:334-339.